Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech IPO hopeful rEVO puts off its plans for a $75M debut By Damian Garde Oct 3, 2014 11:35am Massachusetts biotech rEVO Biologics is postponing its efforts to go public in a $75 million IPO. The company, formerly called GTC Therapeutics, had planned to spend its haul on developing its lead drug, ATryn, to treat preeclampsia. More